870221-22-0Relevant articles and documents
Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor
Hodous, Brian L.,Geuns-Meyer, Stephanie D.,Hughes, Paul E.,Albrecht, Brian K.,Bellon, Steve,Bready, James,Caenepeel, Sean,Cee, Victor J.,Chaffee, Stuart C.,Coxon, Angela,Emery, Maurice,Fretland, Jenne,Gallant, Paul,Gu, Yan,Hoffman, Doug,Johnson, Rebecca E.,Kendall, Richard,Kim, Joseph L.,Long, Alexander M.,Morrison, Michael,Olivieri, Philip R.,Patel, Vinod F.,Polverino, Anthony,Rose, Paul,Tempest, Paul,Wang, Ling,Whittington, Douglas A.,Zhao, Huilin
, p. 611 - 626 (2007/10/03)
Inhibition of angiogenesis is a promising and clinically validated approach for limiting tumor growth and survival. The receptor tyrosine kinase Tie-2 is expressed almost exclusively in the vascular endothelium and is required for developmental angiogenes
PROTEIN KINASE MODULATORS AND METHOD OF USE
-
Page/Page column 135, (2010/02/14)
The present invention relates to chemical compounds having a general formula I wherein A, B, D, E, G, H1-5 and R1-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compounds are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other poliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of protein kinases.